Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 260,000 Shares

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 260,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $18.23, for a total transaction of $4,739,800.00. Following the completion of the sale, the director owned 5,144,998 shares in the company, valued at $93,793,313.54. The trade was a 4.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63.

Vor Biopharma Stock Performance

Shares of NASDAQ VOR traded down $1.78 during midday trading on Monday, hitting $16.27. 1,483,006 shares of the company’s stock were exchanged, compared to its average volume of 1,175,652. Vor Biopharma Inc. has a twelve month low of $2.62 and a twelve month high of $65.80. The stock’s 50 day moving average price is $14.25 and its 200-day moving average price is $17.35.

Wall Street Analysts Forecast Growth

VOR has been the subject of several recent analyst reports. Wedbush increased their price target on Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. JPMorgan Chase & Co. cut their price objective on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Wall Street Zen upgraded shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Saturday. Wells Fargo & Company began coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price on the stock. Finally, TD Cowen began coverage on shares of Vor Biopharma in a research report on Wednesday, December 17th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $50.67.

Institutional Trading of Vor Biopharma

Institutional investors have recently modified their holdings of the company. Ariose Capital Management Ltd bought a new position in Vor Biopharma during the third quarter valued at about $5,368,000. Fcpm Iii Services B.V. acquired a new stake in Vor Biopharma in the 3rd quarter valued at about $18,496,000. Jane Street Group LLC acquired a new stake in Vor Biopharma in the 1st quarter valued at about $140,000. Susquehanna Portfolio Strategies LLC bought a new position in shares of Vor Biopharma during the 4th quarter valued at about $134,000. Finally, XTX Topco Ltd acquired a new position in shares of Vor Biopharma in the 2nd quarter worth approximately $66,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).